WuXi XDC Wins Best ADC CDMO and Best ADC CRDMO Awards at the Asia-Pacific Biopharma Excellence Awards 2026

WuXi XDC Wins Best ADC CDMO and Best ADC CRDMO Awards at the Asia-Pacific Biopharma Excellence Awards 2026

Recognising Excellence in Antibody-Drug Conjugate Development and Manufacturing  

Singapore, 13 March 2026 – WuXi XDC, a leading global contract research, development and manufacturing organisation dedicated to antibody-drug conjugates (ADCs) and other complex bioconjugates, has received two prestigious honours at the Asia-Pacific Biopharma Excellence Awards 2026, held on 11 March at the Sands Expo & Convention Centre in Singapore.  

A total of 92 awards were presented, recognising outstanding achievements in areas such as bioprocessing innovation, biologics manufacturing, supply chain excellence, and emerging technologies that are advancing the industry.

The company was recognised in the following categories:  

Best ADC CDMO Award
Best ADC CRDMO Award

These awards recognise WuXi XDC’s continued leadership in advancing ADC discovery, development, and manufacturing, supporting global biopharma companies in accelerating the development of next-generation targeted therapies.  

Through its integrated end-to-end platform, WuXi XDC provides comprehensive capabilities spanning bioconjugation technology, process development, analytical services, and commercial manufacturing, enabling partners to efficiently progress ADC candidates from early discovery through clinical development and commercialisation.  

“What distinguishes WuXi XDC is our fully integrated CRDMO platform, delivering end-to-end services from early discovery through to commercial manufacturing,” said Dr Jun Hun, VP, Head of XDC CEC and Singapore Site Management, WuXi XDC, who accepted the award on behalf of the company. “By consolidating the entire ADC supply chain and combining advanced technologies with multidisciplinary expertise, we help partners streamline development, accelerate timelines, and reduce risk.”  

“As more ADC programmes advance into late-stage and commercial development, we are strategically expanding our global manufacturing footprint to meet growing demand,” said Dr Jun Hun, VP, Head of XDC CEC and Singapore Site Management, WuXi XDC. “Our new commercial manufacturing facility in Singapore will further strengthen our ability to support partners worldwide.”  

With a strong focus on innovation, quality, and speed, WuXi XDC supports the growing global demand for complex modalities such as ADCs, helping biopharma innovators bring transformative cancer therapies to patients faster.  

Watch the exclusive winner’s interview with Dr Jun Hun, VP, Head of XDC CEC and Singapore Site Management, WuXi XDC, who accepted the award on behalf of the company, sharing what these awards mean for their team and their vision for advancing ADC innovation: https://www.imapac.com/news-updates/abea2026-exclusive-interview-with-dr-jun-hun-vp-head-of-xdc-cec-and-singapore-site-management-wuxi-xdc  

About WuXi XDC  

WuXi XDC (2268.HK) is a leading global CRDMO dedicated to antibody-drug conjugates (ADCs) and the broader bioconjugate market, providing end-to-end contract research, development, and manufacturing services. Its integrated platform supports the entire ADC value chain, covering antibody and biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products, enabling biopharma partners to accelerate the development of next-generation targeted therapies.  

Through its international reach and strong local expertise, Southern Star Research enables multi-regional clinical trials, acting as a trusted advisor to guide sponsors through complex development pathways and accelerate successful study outcomes.  

About IMAPAC  

IMAPAC is a global market intelligence and business networking company specialising in life sciences, biopharmaceutical manufacturing, clinical research, and healthcare innovation. Through industry conferences, executive forums, and research-driven initiatives, IMAPAC connects senior leaders across the biopharmaceutical ecosystem to drive collaboration, innovation, and knowledge exchange.  

IMAPAC organises leading industry platforms across Asia, Europe, and North America, bringing together stakeholders from biopharma companies, contract service providers, regulators, and technology innovators to address the evolving challenges shaping the future of life sciences.  

About the Asia-Pacific Biopharma Excellence Awards  

The Asia-Pacific Biopharma Excellence Awards (ABEA) recognise outstanding organisations, technologies, and leaders driving innovation and excellence across the bioprocessing and biopharmaceutical manufacturing landscape in the Asia-Pacific region.  

Presented annually by IMAPAC, the awards celebrate achievements across categories including biologics development, manufacturing, outsourcing, digitalisation, and operational excellence, recognising organisations advancing the development of next-generation therapies.